Stephen Mandel Jr.’s Greenwich, Connecticut–based Lone Pine Capital made several significant changes to the top holdings in Lone Cypress, the firm’s flagship long-short equity fund.
But perhaps most significant is that Lone Cypress stood pat with its large position in Valeant Pharmaceuticals International.
